ATOS: Multiple Catalysts Converge in 2H26
On Aug. 7, 2026, Atossa Therapeutics, Inc. (ATOS) announced financial results for the second quarter of 2026 and provided a business update. The...
102 Views
ATOS: Raises up to 16.5 Million in Registered Direct Offering
In June 2026, Atossa Therapeutics, Inc. (ATOS) announced the closing of a registered direct offering of 1,363,637 shares of its common stock and...
127 Views
ATOS: Initiating Coverage of Atossa Therapeutics Endoxifen's Expanding Opportunity from Oncology to Orphan Disease
We are initiating coverage of Atossa Therapeutics, Inc. (ATOS) with a valuation of $22.00. Atossa is a clinical-stage biopharmaceutical company...
114 Views
Atossa Therapeutics Inc - May 13, 2026
We are initiating coverage of Atossa Therapeutics, Inc. (ATOS) with a valuation of $22.00. Atossa is a clinical-stage biopharmaceutical company...
120 Views
Atossa Genetics - Endoxifen to start Phase II studies shortly
Atossa Genetics is preparing to start Phase II studies of both its oral and topical endoxifen formulations in Q218. Endoxifen, an estrogen receptor...
225 Views